The Community Advisory Board (CAB) constitutes a space of exchange between advocates from the MENA region, researchers and drug manufacturers, with the aim to educate people living with HIV and their advocates on access to treatment, to disseminate information about research and drug development and to discuss access strategies. The organisation of the CABs is justified by the need to address national and regional specificities and also to meet with local/regional representatives of drug companies as well as local research teams.
In 2017, ITPC-MENA hosted its first MENA-CAB on HIV and Hep C and created an opportunity for the advocates from all over the region to effectively engage with companies on HIV, Hep C, diagnostics and treatment pricing, patents and registration issues.
This report cover the second MENACAB meeting held in Marrakesh Morocco from 23rd to 24th November 2017. Eighteen participants from eight countries of the MENA region attended the meetings with the objectives of :
- Improving access to strategic information for people living with HIV and/or HCV to equip them for effective advocacy for Universal Access at country and the MENA regional level.
- Developing and strengthing a network of treatment advocates.
- Providing expert training on current treatment issues and opportunities to meet with doctors, researchers and pharmaceutical companies.
The report represents a synthesis of the meetings held with the pharmaceutical companies and addresses all the issues raised during these meeting
For further informations, please contact our Advocacy Officer : firstname.lastname@example.org.
To download the report: Rapport MENACAB 2017 LOW